Organization
Fundación Jiménez Díaz
4 abstracts
Abstract
A phase 1/2 study of CFT1946, a novel, bifunctional degradation activating compound (BIDAC) degrader, of mutant BRAF V600 as monotherapy and in combination with trametinib, in mutant BRAF V600 solid tumors.Org: Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, Virginia Cancer Specialists, Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
Clinical analysis of the presence of comutations in patients with EGFR-mutated NSCLC.Org: University Hospital Fundación Jiménez Díaz, Hospital Universitario Fundación Jiménez Díaz, Fundacion Jimenez Diaz University Hospital, Fundación Jiménez Díaz, University Hospital Fundacion Jimenez Diaz,
Abstract
Safety analysis of lurbinectedin versus topotecan in elderly patients.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Fondazione IRCCS - Istituto Nazionale dei Tumori, Fondazione Policlinico Gemelli IRCCS, Hospital Universitario Virgen de la Victoria, Institut Gustave Roussy,
Abstract
A 7-YEARS EXPERIENCE OF PERCUTANEOUS VERTEBROPLASTY FOR OSTEOPOROTIC VERTEBRAL FRACTURES: ANALYSIS OF FACTORS DETERMINING OUTCOME IN 212 PATIENTSOrg: Orthopaedics, Neuroradiology, Epidemiology Laboratory, Clinical Research, and Community Health, Faculty of Medicine, Pharmacy and Dental Medicine of Fez, University of Sidi Mohamed Ben Abdellah, Fez, Morocco, Fundación Jiménez Díaz, Madrid, Spain,